**This Weight-Loss Solution Becomes India’s Second-Highest Selling Drug**
*By Dwaipayan Roy | Oct 08, 2025*
—
**What’s the story?**
Eli Lilly’s anti-obesity and diabetes drug, Mounjaro, has taken the Indian pharmaceutical market by storm. Within just six months of its launch, the drug has become the second-best selling medication in India amid a rising demand for effective weight-loss therapies across the country.
According to data from the Indian Pharmaceutical Market (IPM), Mounjaro achieved sales worth ₹80 crore in September alone, accumulating a total revenue of ₹233 crore since its introduction.
—
**Market Performance**
Mounjaro’s sales have surged impressively, witnessing a 43% growth from August to September. This rapid rise has positioned the drug as a strong competitor to GSK’s Augmentin, which currently leads the IPM with retail monthly sales of ₹85 crore.
Industry analysts attribute Mounjaro’s success largely to its user-friendly pen formulation, which enhances ease of administration. Additionally, recent Goods and Services Tax (GST) cuts are expected to further accelerate its market penetration in the coming months.
—
**Product Details**
Launched in India in late March, Mounjaro offers a weight-loss efficacy of approximately 20-22%. The drug’s popularity received a significant boost in August with the introduction of its injectable Kwikpens. These disposable, pre-filled pens come in various dosages priced between ₹14,000 and ₹27,500.
—
**Sales Forecast**
The recent reduction in GST from 18% to 5%, effective from September 22, has substantially lowered the financial burden on chronic care patients. This tax cut is poised to enhance Mounjaro’s sales momentum further, making it more accessible for a broader population.
—
With its strong efficacy, convenient delivery method, and favorable pricing post-GST cuts, Mounjaro is set to continue its impressive growth trajectory in India’s pharmaceutical landscape.
https://www.newsbytesapp.com/news/business/eli-lilly-s-mounjaro-becomes-2nd-best-selling-drug-in-india/story
